{"schema_version":"secwatch.filing_event.v1","accession":"0000784199-23-000014","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.081024+00:00","generated_at":"2026-06-19T09:55:42.239679+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Artivion Q4 GAAP EPS $0.05 vs ($0.51) loss; 2023 revenue outlook $331M-$343M","bullets":["Q4 revenue $79.4M, flat GAAP, +5% constant currency; On-X +11% CC, aortic stent grafts +16% CC.","GAAP net income $2.2M ($0.05 EPS) vs net loss $20.1M ($0.51); non-GAAP $4.2M ($0.10).","FY2022 revenue $313.8M (+5% GAAP, +9% CC); net loss $19.2M ($0.48) vs $14.8M ($0.38) in 2021.","Received CE mark for BioGlue under EU MDR in Q4 2022.","2023 guidance: CC revenue growth 8-12%, revenue $331M-$343M, adjusted EBITDA >$50M (+20%)."],"urls":{"canonical":"https://secwatch.observer/filing/0000784199-23-000014","json":"https://secwatch.observer/filing/0000784199-23-000014.json","markdown":"https://secwatch.observer/filing/0000784199-23-000014.md","text":"https://secwatch.observer/filing/0000784199-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000078419923000014/0000784199-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000078419923000014/aort-20230216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T09:55:42.239679+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0deccbbe9060812d1c216a484335fc77653e81a9","claim":"ARTIVION, INC. reported the fourth quarter ended December 31, 2022 results: revenue $79.4 million, net income $2.2 million, EPS $0.05 per fully diluted common share. Guidance reaffirmed.","evidence_excerpt":"Total revenues for the fourth quarter of 2022 were $79.4 million, flat on a GAAP basis and an increase of 5% on a non-GAAP constant currency basis, both compared to the fourth quarter of 2021. Net income for the fourth quarter of 2022 was $2.2 million, or $0.05 per fully diluted common share, compared to net loss of ($20.1) million, or ($0.51) per fully diluted common share for the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/784199/000078419923000014/0000784199-23-000014-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$79.4 million"},{"label":"Net income","value":"$2.2 million"},{"label":"EPS","value":"$0.05 per fully diluted common share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"1ed1cd6eac856a87073375c815abb2f76f2e4806","claim":"ARTIVION, INC. reported the full year ended December 31, 2022 results: revenue $313.8 million, net income ($19.2) million, EPS ($0.48) per fully diluted common share. Guidance reaffirmed.","evidence_excerpt":"Total revenues for 2022 were $313.8 million, reflecting an increase of 5% on a GAAP basis and 9% on a non-GAAP constant currency basis compared to the full year of 2021. Net loss for 2022 was ($19.2) million, or ($0.48) per fully diluted common share, compared to net loss of ($14.8) million, or ($0.38) per fully diluted common share for the full year of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/784199/000078419923000014/0000784199-23-000014-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Revenue","value":"$313.8 million"},{"label":"Net income","value":"($19.2) million"},{"label":"EPS","value":"($0.48) per fully diluted common share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}